Growth hormone therapy in Noonan's syndrome: non-cardiomyopathic congenital heart disease does not adversely affect growth improvement.
Twenty-three children with Noonan's syndrome were treated with growth hormone (GH) and followed for at least three years. The presence of cardiomyopathy was a contraindication to treatment. Height SDS and velocity increased during treatment. None of the 23 children developed hypertrophic cardiomyopathy during GH treatment. Children with any cardiac abnormality at the start of treatment did not show a reduced growth trend when compared with patients with normal hearts.
Brown
D C
DC
Child Life & Health, University of Edinburgh, London, UK. donald.brown@luht.scot.nhs.uk
Macfarlane
C E
CE
McKenna
W J
WJ
Patton
M A
MA
Dunger
D B
DB
Savage
M O
MO
Kelnar
C J H
CJ
D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D006332:Cardiomegaly / Q000150:complications / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006128:Growth / Q000187:drug effects*; D013006:Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D006330:Heart Defects, Congenital / Q000150:complications*; D006801:Humans; D008297:Male; D009634:Noonan Syndrome / Q000188:drug therapy*
D013006:Growth Hormone